Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002707 · ClinicalTrials.gov registry record · Phase 3
Chemotherapy in Treating Women With Breast Cancer That Can Be Surgically Removed
A Phase 3 study of Breast Cancer, sponsored by NSABP Foundation.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,411
- Enrollment target
- 20
- Study locations
NCT00002707: Completed Phase 3 study of Breast Cancer, sponsored by NSABP Foundation.
NCT00002707 is a Phase 3 study of Breast Cancer that has completed, run by NSABP Foundation. The registered enrollment target is 2,411 participants, below the 2,801-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (14% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002707, a Phase 3 study of Breast Cancer, has completed, sponsored by NSABP Foundation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,411 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if chemotherapy given before surgery is more effective with or without docetaxel given before or after surgery for breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy using doxorubicin and cyclophosphamide with or without docetaxel in treating women who have stage II or stage III breast cancer.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Docetaxel
- DRUG Doxorubicin
- DRUG Tamoxifen
Study Locations (20)
California
- Sutter Health Western Division Cancer Research Group - Greenbrae
- Loma Linda University Medical Center - Loma Linda
- Saint Mary Medical Center - Long Beach - Long Beach
- Beckman Research Institute, City of Hope - Los Angeles
- CCOP - Bay Area Tumor Institute - Oakland
- Chao Family Comprehensive Cancer Center - Orange
- Comprehensive Cancer Centers of the Desert - Palm Springs
- Kaiser Permanente-Southern California Permanente Medical Group - San Diego
- Catholic Healthcare West - Westbay Region - San Francisco
- CCOP - Santa Rosa Memorial Hospital - Santa Rosa
- Kaiser Permanente Medical Center - Vallejo - Vallejo
Colorado
- CCOP - Colorado Cancer Research Program, Inc. - Denver
- University of Colorado Cancer Center - Denver
Connecticut
- University of Connecticut Health Center - Farmington
- Hartford Hospital - Hartford
Alabama
- Huntsville Hospital System - Huntsville
Arizona
- CCOP - Greater Phoenix - Phoenix
Delaware
- CCOP - Christiana Care Health Services - Wilmington
District of Columbia
- George Washington University Cancer Center - Washington D.C.
Florida
- Halifax Medical Center - Daytona Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,411 participants |
| Start Date | 1995-12 |
| Est. Completion | 2010-02 |
| Phase | Phase 3 |
What the finished NCT00002707 record still lists
NCT00002707 is an interventional study that assigns participants to a tested intervention. Its 2,411 participants enrollment target places it among the larger protocols in the corpus, below the 2,801-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (14% lower).
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT00002707 names 20 study sites across 8 states, led by California, Colorado, Connecticut.
Frequently Asked Questions
What is clinical trial NCT00002707 about?
NCT00002707 is a clinical study titled "Chemotherapy in Treating Women With Breast Cancer That Can Be Surgically Removed". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if chemotherapy given before surgery is more effective with or without docetaxel given before or after surgery for breast cancer. PURPOSE: Randomized phase III...
What is the current status of trial NCT00002707?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,411 participants. The study started on 1995-12. Estimated completion is 2010-02.
What conditions does trial NCT00002707 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT00002707?
The interventions under investigation include: Cyclophosphamide (DRUG), Docetaxel (DRUG), Doxorubicin (DRUG), Tamoxifen (DRUG).
Who is sponsoring clinical trial NCT00002707?
This trial is sponsored by NSABP Foundation, which has 44 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002707 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00002707's enrollment target sits among peer trials
2,411 61st of 1224 higher than 1,164 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
RECRUITING · Phase 3
-
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
RECRUITING · Phase 3
-
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
RECRUITING · Phase 3
-
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
RECRUITING · Phase 3
-
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05873387 · 2,420 participants
Development of an Algorithm to Detect Pulmonary Hypertension Using an Electronic Stethoscope
- NCT05185440 · 2,400 participants · NA
Reducing Alcohol Involved Sexual Violence in Higher Education
- NCT05285527 · 2,400 participants · NA
MiSight 1 Day Safety Post-Approval Study
- NCT05738330 · 2,400 participants · NA
Symptom Monitoring in Hemodialysis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia